Foghorn Therapeutics Inc (FHTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $124.12M
Last updated: Nov 17, 2026 at 11:05 AM ET
Foghorn Therapeutics Inc (FHTX) Competitors
The companies most similar to Foghorn Therapeutics are Fate Therapeutics (FATE), Whitehawk Therapeutics (WHWK) and Compass Therapeutics (CMPX). By market cap, Foghorn Therapeutics ranks 8th of the 13 companies on this page; Fulcrum Therapeutics (FULC) is the largest at $287.96M.
Peer Comparison
FHTX's revenue growth of 925.0% is above the peer median of -32.4%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Foghorn Therapeutics (FHTX) | $124.12M | 40.1x | 1.1x | 8.4% | N/A | 925.0% | 0.00% |
| Fate Therapeutics Inc (FATE) | $155.74M | N/A | 29.7x | 0.0% | -51.3% | 9.2% | 0.00% |
| Whitehawk Therapeutics, Inc. (WHWK) | $180.57M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Compass Therapeutics Inc. (CMPX) | $139.35M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Voyager Therapeutics Inc (VYGR) | $107.66M | N/A | 4.0x | 0.0% | N/A | -70.0% | 0.00% |
| Fulcrum Therapeutics Inc (FULC) | $287.96M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Gossamer Bio Inc (GOSS) | $67.10M | N/A | 0.9x | -159.5% | 147.4% | 189.1% | 0.00% |
| Corbus Pharmaceuticals Holding (CRBP) | $69.86M | N/A | 13.9x | 0.0% | -106.7% | -100.0% | 0.00% |
| Invivyd Inc. (IVVD) | $171.58M | N/A | 2.9x | -183.9% | N/A | 21.2% | 0.00% |
| LENZ Therapeutics Inc (LENZ) | $129.77M | N/A | 9.7x | 0.0% | N/A | -72.9% | 0.00% |
| MacroGenics Inc (MGNX) | $140.60M | N/A | 1.2x | -36.6% | -108.7% | -64.8% | 0.00% |
| Neumora Therapeutics, Inc. (NMRA) | $80.59M | N/A | N/A | 0.0% | -260.5% | 0.0% | 0.00% |
| Minerva Neurosciences Inc (NERV) | $114.62M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $134.56M | N/A | 4.0x | 0.0% | -106.7% | -32.4% | 0.00% |
Similar Companies
These are the 12 companies most similar to Foghorn Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Fate Therapeutics Inc (FATE) | Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally. | FATE competitors |
| Whitehawk Therapeutics, Inc. (WHWK) | Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. | WHWK competitors |
| Compass Therapeutics Inc. (CMPX) | Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple... | CMPX competitors |
| Voyager Therapeutics Inc (VYGR) | Voyager Therapeutics, Inc., a clinical-stage gene therapy company, is focused on developing treatments for patients with severe neurological diseases. | VYGR competitors |
| Fulcrum Therapeutics Inc (FULC) | Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined... | FULC competitors |
| Gossamer Bio Inc (GOSS) | Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing... | GOSS competitors |
| Corbus Pharmaceuticals Holding (CRBP) | Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapies that target... | CRBP competitors |
| Invivyd Inc. (IVVD) | Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery... | IVVD competitors |
| LENZ Therapeutics Inc (LENZ) | LENZ Therapeutics Inc is a cutting-edge biopharmaceutical company dedicated to developing transformative therapies for neurological disorders... | LENZ competitors |
| MacroGenics Inc (MGNX) | MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States. | MGNX competitors |
| Neumora Therapeutics, Inc. (NMRA) | Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases... | NMRA competitors |
| Minerva Neurosciences Inc (NERV) | Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of candidate products... | NERV competitors |
Frequently Asked Questions About FHTX
Who are Foghorn Therapeutics' main competitors?
The companies most similar to Foghorn Therapeutics include Fate Therapeutics (FATE), Whitehawk Therapeutics (WHWK), Compass Therapeutics (CMPX), Voyager Therapeutics (VYGR) and Fulcrum Therapeutics (FULC), listed from the closest match.
Who is Foghorn Therapeutics' biggest competitor?
Fulcrum Therapeutics (FULC) is the largest of the similar companies at $287.96M; Fate Therapeutics (FATE) is the closest match by business profile, size, sector and industry.
How does FHTX stock compare with its competitors?
FHTX's P/S is 1.1x against a peer median of 4.0x; its net margin is 8.4% against a peer median of 0.0%.
Which of Foghorn Therapeutics' competitors pays a higher dividend?
Foghorn Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Foghorn Therapeutics bigger than its competitors?
No. Foghorn Therapeutics is 8th by market cap among the 13 companies on this page; the largest is Fulcrum Therapeutics (FULC) at $287.96M.
FHTX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors